Sunshine Biopharma Launches Generic Doxycycline for STD, Acne, and Lyme Disease in Canada.

Sunshine Biopharma launches generic Doxycycline in Canada, a broad-spectrum antibiotic used to treat respiratory tract infections, urinary tract infections, sexually transmitted diseases, acne, and tick-borne illnesses like Lyme disease. The Canadian market is part of the North American segment projected to grow steadily through 2030, with the global market valued at $729 million in 2024 and expected to reach $1.2 billion by 2030, according to a StockTitan report. This launch aligns with the company's mission to deliver high-quality, affordable medications that meet real clinical needs.

Sunshine Biopharma Inc. (NASDAQ: SBFM) has announced the commercial launch of generic Doxycycline in Canada. The product, available as 100 mg tablets, is now accessible to pharmacies, hospitals, and healthcare providers nationwide. This strategic move strengthens the company's presence in the Canadian antibiotic market and aligns with its broader expansion into anti-infective therapies.

Doxycycline is a broad-spectrum antibiotic used to treat respiratory tract infections, urinary tract infections, sexually transmitted diseases, acne, and tick-borne illnesses such as Lyme disease. With high oral bioavailability and a long half-life, it remains a first-line treatment across multiple antibacterial areas.

The Canadian Doxycycline market is part of a broader North American segment projected to grow steadily through 2030. The North American market is expected to contribute significantly to the global market, which was valued at approximately $729 million in 2024 and is forecasted to reach $1.2 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.6%.

Sunshine Biopharma's doxycycline is manufactured in compliance with Health Canada's regulatory framework, ensuring therapeutic equivalence to the reference product. Distribution is underway through established pharmacy networks and hospital channels.

This launch follows Sunshine Biopharma's recent expansion into anti-infective therapies and complements the company's growing pipeline of generic drugs targeting infectious diseases, oncology, and metabolic disorders. Sunshine Biopharma currently has 76 generic prescription drugs on the market in Canada and more than 12 additional drugs scheduled to be launched in 2026.

Dr. Steve Slilaty, CEO of Sunshine Biopharma, commented, "Launching Doxycycline in Canada aligns with our mission to deliver high-quality, affordable medications that meet real clinical needs. We are proud to support healthcare providers with a trusted antibiotic backed by rigorous manufacturing and regulatory standards."

For more information, please visit: www.sunshinebiopharma.com.